Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The fibrates have been used for many years to treat dyslipidemias and have also recently been shown to have anti-inflammatory effects. They are relatively weak PPAR-α agonists and do have some adverse effects. Novel compounds are in development, which are selective PPAR modulators (SPPARMs) and have more potent PPAR-α agonist activity. These may prove to have advantages in the treatment of dyslipidemia, insulin resistance and non-alcoholic fatty liver disease (NAFLD). AREAS COVERED: This review focuses on PPAR-α agonists or SPPARMs in development describing the preclinical and early clinical studies. The information was obtained by searching the published literature and abstracts from recent meetings. Ongoing clinical trials were identified using the Clinicaltrial.gov database. EXPERT OPINION: There is still a need for new drugs to treat atherogenic dyslipidemia. The highly potent and selective PPAR-α agonist K-877 has shown beneficial effects on atherogenic dyslipidemia and absence of some adverse effects seen with fibrates. The dual PPAR-α/PPAR-δ agonist GFT-505 has shown favorable results in improving atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate for the treatment of NAFLD. Long-term trials are needed to assess the safety and efficacy of these new agents for cardiovascular and liver outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 1×
“Before the use of statins, clinical trials with gemfibrozil showed beneficial effects on cardiovascular events in the Helsinki Heart Study [26] and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial study [27].”
MethodEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“The cholesterol ester transport protein inhibitors provide an attractive new mechanism for increasing HDL-C and reducing LDL-C but the failure in Phase III trials of torcetrapib with off-target effects including increase in blood pressure [78], and of dalcetrapib in the dal-OUTCOMES study for futility are disappointin…”
BackgroundNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“The more recent Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid study tested whether the addition of fenofibrate to treatment with simvastatin in patients with T2DM at high risk of CVD could improve the combined cardiovascular event outcome [34].”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 2×
“Similar findings were noted in the secondary prevention Bezafibrate Infarction Prevention study where bezafibrate did not significantly reduce the primary end point in the overall study but did reduce it in a sub group of patients with high baseline triglycerides (‡ 200 mg/dl or 2.3 mmol/l) and in a later analysis ide…”
InfluentialEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · cited 1×
“The two large studies that examined the addition of niacin in patients already on aggressive LDL-C lowering treatment with statin with or without ezetimibe showed no benefit and identified new adverse effects of infection and bleeding in addition to the known adverse effects of niacin such as increasing glucose levels…”
BackgroundEffects of medical therapies on retinopathy progression in type 2 diabetes
The ACCORD Study Group and ACCORD Eye Study Group (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001288 · Cited by 1,311 · cited 1×
“control, reduced the rate of progression of diabetic retinopathy [39].”
BackgroundEffects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927 · cited 1×
“Two meta-analyses of large cardiovascular outcome studies with fibrates found they reduced the risk of major cardiovascular events predominantly by reduction of non-fatal myocardial infarction [35,36].”
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635 · cited 1×
“A recent expert review by the EAS Consensus Panel considered the accumulating epidemiological and genetic data and concluded that mild-to-moderate hypertriglyceridemia was associated with increased risk for CVD and this may require treatment with medication in addition to statins in appropriate cases [9].”
BackgroundScott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · cited 1×
“The liver-protective effects of GFT505 were demonstrated in various animal models of NAFLD/NASH and liver fibrosis including WD-fed hApoE2 KI transgenic mice and the benefits were shown to be partly related to PPAR-a effects and partly due to PPAR-a-independent mechanisms [69].”
BackgroundWithdrawal of Cerivastatin from the World Market
Furberg, C. D., & Pitt, B. (2001) · Trials · doi:10.1186/cvm-2-5-205 · Cited by 400
on behalf of the FIELD Study investigators, Davis, T. M. E., Ting, R., Best, J. D., Donoghoe, M. W., Drury, P. L., Sullivan, D. R., Jenkins, A. J., O’Connell, R. L., Whiting, M. J., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-1951-1 · Cited by 371 · cited 1×
“In the FIELD study, fenofibrate reduced albuminuria and slowed the loss in eGFR over 5 years, but did not reduce the frequency of end-stage renal events [40].”
BackgroundRajamani, K., Colman, P. G., Li, L. P., Best, J. D., Voysey, M., D'Emden, M. C., Laakso, M., Baker, J. R., & Keech, A. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60698-x · Cited by 328
Rabar, S., Harker, M., O'Flynn, N., Wierzbicki, A. S., & On behalf of the Guideline Development Group (2014) · BMJ · doi:10.1136/bmj.g4356 · Cited by 292 · cited 1×
“Some guidelines, such as the recent National Institute for Health and Care Excellence guidance [10], consider the plasma nonHDL-cholesterol (non-HDL-C) level as a better target than LDL-C levels as non-HDL-C includes the cholesterol carried in triglyceride-rich particles.”
BackgroundFruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233
Stemming the global tsunami of cardiovascular disease
Anand, S. S., & Yusuf, S. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62346-x · Cited by 216 · cited 1×
“Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity in developed countries and is becoming the major cause of mortality in developing countries [1].”
BackgroundFabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Fruchart, J.-C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-82 · Cited by 189
Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., & Karpe, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0111 · Cited by 153 · cited 1×
“Circulating FGF21 in humans increased significantly in response to treatment with PPAR-a and PPAR-d, but not PPAR-g agonists and this may contribute to the beneficial metabolic effects observed in response to pharmacotherapy with these compounds [45].”
BackgroundYamazaki, Y., Abe, K., Toma, T., Nishikawa, M., Ozawa, H., Okuda, A., Araki, T., Oda, S., Inoue, K., Shibuya, K., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.066 · Cited by 84 · cited 1×
“phenoxyalkyl side-chains to enhance PPAR-a activity and selectivity (Figure 2) [22,56].”
Background
Cited by
Hennuyer, N., Duplan, I., Paquet, C., Vanhoutte, J., Woitrain, E., Touche, V., Colin, S., Vallez, E., Lestavel, S., Lefebvre, P., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.003 · Cited by 132
Novel therapeutics in hypertriglyceridemia
Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44
Effects of pemafibrate on primary biliary cholangitis with dyslipidemia
Yamaguchi, M., Asano, T., Arisaka, T., Mashima, H., Irisawa, A., & Tamano, M. (2022) · Hepatology Research · doi:10.1111/hepr.13747 · Cited by 23
“As such, PEM is also known as a selective PPAR‐α modulator, and its effect on PPARα activation is considered 50 000 times greater than that of BEZ.(25,26) In a mouse model of nonalcoholic steatohepatitis (NASH), PEM has gained much attention because it was shown to suppress the progression of NASH and show histologica…”
BackgroundInfluential
Metadata
- Authors
- Liu, Z.-M., Hu, M., Chan, P., & Tomlinson, B.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2015-01-21
- Volume
- 24
- Issue
- 5
- Pages
- 611-621
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2051656202
- Cited by
- 45
- References
- 24
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.